المؤلفون: Meagher, Margaret, Minervini, Andrea, Mir, Maria, Cerrato, Clara, Rebez, Giacomo, Autorino, Riccardo, Hampton, Lance, Campi, Riccardo, Kriegmair, Maximilian, Linares, Estefania, Hevia, Vital, Musquera, Maria, DAnna, Mauricio, Roussel, Eduard, Albersen, Maarten, Pavan, Nicola, Claps, Francesco, Antonelli, Alessandro, Marchioni, Michele, Paksoy, Nail, Erdem, Selcuk, Derweesh, Ithaar

مصطلحات موضوعية: Immunotherapy, Metastatic renal cell carcinoma, Nephrectomy, Survival, Tyrosine kinase inhibitor

الوصف: BACKGROUND AND OBJECTIVE: The role of cytoreductive nephrectomy (CN) in the treatment of metastatic renal cell carcinoma (mRCC) has been called into question on the basis of clinical trial data from the tyrosine kinase inhibitor (TKI) era. Comparative analyses of CN for patients treated with immuno-oncology (IO) versus TKI agents are sparse. Our objective was to compare CN timing and outcomes among patients who received TKI versus IO therapy. METHODS: This was a multicenter retrospective analysis of patients who underwent CN using data from the REMARCC (Registry of Metastatic RCC) database. The cohort was divided into TKI versus IO first-line therapy groups. The primary outcome was all-cause mortality (ACM). Secondary outcomes included cancer-specific mortality (CSM). Multivariable analysis was used to identify factors predictive for ACM and CSM. The Kaplan-Meier method was used to analyze 5-yr overall survival (OS) and cancer-specific survival (CSS) with stratification by primary systemic therapy and timing in relation to CN. KEY FINDINGS AND LIMITATIONS: We analyzed data for 189 patients (148 TKI + CN, 41 IO +CN; median follow-up 23.2 mo). Multivariable analysis revealed that a greater number of metastases (hazard ratio [HR] 1.06; p = 0.015), greater primary tumor size (HR 1.10; p = 0.043), TKI receipt (HR 2.36; p = 0.015), and initiation of systemic therapy after CN (HR 1.49; p = 0.039) were associated with worse ACM. A greater number of metastases at diagnosis (HR 1.07; p = 0.011), greater primary tumor size (HR 1.12; p = 0.018), TKI receipt (HR 5.43; p = 0.004), and initiation of systemic therapy after CN (HR 2.04; p

وصف الملف: application/pdf

الوصول الحر: https://escholarship.org/uc/item/5wj3c1wmTest
https://escholarship.org/content/qt5wj3c1wm/qt5wj3c1wm.pdfTest

المؤلفون: Warren, Hannah, Rautio, Aleksandra, Marandino, Laura, Pyrgidis, Nikolaos, Tzelves, Lazaros, Roussel, Eduard, Muselaers, Stijn, Erdem, Selcuk, Palumbo, Carlotta, Amparore, Daniele, Wu, Zhenjie, Ciccarese, Chiara, Diana, Pietro, Borregales, Leonardo, Pavan, Nicola, Pecoraro, Angela, Caliò, Anna, Klatte, Tobias, Carbonara, Umberto, Marchioni, Michele, Bertolo, Riccardo, Campi, Riccardo, Tran, Maxine GB

المصدر: European Urology Open Science , 62 pp. 54-60. (2024) (In press).

مصطلحات موضوعية: Biopsy, Kidney cancer, Small renal mass

الوصف: Background and objective: Renal tumour biopsy (RTB) can help in risk stratification of renal tumours with implications for management, but its utilisation varies. Our objective was to report current practice patterns, experiences, and perceptions of RTB and research gaps regarding RTB for small renal masses (SRMs). Methods: Two web-based surveys, one for health care providers (HCPs) and one for patients, were distributed via the European Association of Urology Young Academic Urologist Renal Cancer Working Group and the European Society of Residents in Urology in January 2023. Key findings and limitations: The HCP survey received 210 responses (response rate 51%) and the patient survey 54 responses (response rate 59%). A minority of HCPs offer RTB to >50% of patients (14%), while 48% offer it in <10% of cases. Most HCPs reported that RTB influences (61.5%) or sometimes influences (37.1%) management decisions. Patients were more likely to favour active treatment if RTB showed highgrade cancer and less likely to favour active treatment for benign histology. HCPs identified situations in which they would not favour RTB, such as cystic tumours and challenging anatomic locations. RTB availability (67%) and concerns about delays to treatment (43%) were barriers to offering RTB. Priority research gaps include a trial demonstrating that RTB leads to better clinical outcomes, and better evidence that benign/indolent tumours do not require active treatment. Conclusions and clinical implications: Utilisation of RTB for SRMs in Europe is low, even though both HCPs and patients reported that RTB results can affect disease management. Improving timely access to RTB and generating evidence on outcomes associated with RTB use are priorities for the kidney cancer community. Patient summary: A biopsy of a kidney mass can help patients and doctors make decisions on treatment, but our survey found that many patients in Europe are not offered this option. Better access to biopsy services is needed, as well as more research on ...

وصف الملف: text

العلاقة: https://discovery.ucl.ac.uk/id/eprint/10189534/1/1-s2.0-S2666168324002520-main.pdfTest; https://discovery.ucl.ac.uk/id/eprint/10189534Test/

الإتاحة: https://discovery.ucl.ac.uk/id/eprint/10189534/1/1-s2.0-S2666168324002520-main.pdfTest
https://discovery.ucl.ac.uk/id/eprint/10189534Test/

المؤلفون: Minervini, Andrea, Mir, Maria, Cerrato, Clara, Rebez, Giacomo, Autorino, Riccardo, Hampton, Lance, Campi, Riccardo, Kriegmair, Maximilian, Linares, Estefania, Hevia, Vital, Musquera, Maria, DAnna, Mauricio, Roussel, Eduard, Albersen, Maarten, Pavan, Nicola, Claps, Francesco, Antonelli, Alessandro, Marchioni, Michele, Paksoy, Nail, Erdem, Selcuk, Derweesh, Ithaar, Meagher, Margaret

مصطلحات موضوعية: Immunotherapy, Metastatic renal cell carcinoma, Nephrectomy, Survival, Tyrosine kinase inhibitor

الوصف: BACKGROUND AND OBJECTIVE: The role of cytoreductive nephrectomy (CN) in the treatment of metastatic renal cell carcinoma (mRCC) has been called into question on the basis of clinical trial data from the tyrosine kinase inhibitor (TKI) era. Comparative analyses of CN for patients treated with immuno-oncology (IO) versus TKI agents are sparse. Our objective was to compare CN timing and outcomes among patients who received TKI versus IO therapy. METHODS: This was a multicenter retrospective analysis of patients who underwent CN using data from the REMARCC (Registry of Metastatic RCC) database. The cohort was divided into TKI versus IO first-line therapy groups. The primary outcome was all-cause mortality (ACM). Secondary outcomes included cancer-specific mortality (CSM). Multivariable analysis was used to identify factors predictive for ACM and CSM. The Kaplan-Meier method was used to analyze 5-yr overall survival (OS) and cancer-specific survival (CSS) with stratification by primary systemic therapy and timing in relation to CN. KEY FINDINGS AND LIMITATIONS: We analyzed data for 189 patients (148 TKI+CN, 41 IO +CN; median follow-up 23.2 mo). Multivariable analysis revealed that a greater number of metastases (hazard ratio [HR] 1.06; p = 0.015), greater primary tumor size (HR 1.10; p=0.043), TKI receipt (HR 2.36; p=0.015), and initiation of systemic therapy after CN (HR 1.49; p=0.039) were associated with worse ACM. A greater number of metastases at diagnosis (HR 1.07; p=0.011), greater primary tumor size (HR 1.12; p=0.018), TKI receipt (HR 5.43; p=0.004), and initiation of systemic therapy after CN (HR 2.04; p<0.001) were associated with worse CSM. Kaplan-Meier analyses revealed greater 5-yr rates for OS (51% vs 27%; p<0.001) and CSS (83% vs 30%; p<0.001) for IO +CN versus TKI+CN. This difference persisted in a subgroup analysis for patients with intermediate or poor risk, with 5-yr OS rates of 50% for IO+CN versus 30% for TKI+CN (p<0.001). A subanalysis stratified by CN timing revealed better 5-yr ...

وصف الملف: application/pdf

العلاقة: qt5wj3c1wm; https://escholarship.org/uc/item/5wj3c1wmTest

الإتاحة: https://escholarship.org/uc/item/5wj3c1wmTest

المؤلفون: Meagher, Margaret F., Minervini, Andrea, Mir, Maria C., Cerrato, Clara, Rebez, Giacomo, Autorino, Riccardo, Hampton, Lance, Campi, Riccardo, Kriegmair, Maximilian, Linares, Estefania, Hevia, Vital, Musquera, Maria, D'Anna, Mauricio, Roussel, Eduard, Albersen, Maarten, Pavan, Nicola, Claps, Francesco, Antonelli, Alessandro, Marchioni, Michele, Paksoy, Nail, Erdem, Selcuk, Derweesh, Ithaar H.

المصدر: European Urology Open Science ; volume 63, page 71-80 ; ISSN 2666-1683

مصطلحات موضوعية: Urology

الإتاحة: https://doi.org/10.1016/j.euros.2024.02.001Test
https://api.elsevier.com/content/article/PII:S2666168324002490?httpAccept=text/xmlTest
https://api.elsevier.com/content/article/PII:S2666168324002490?httpAccept=text/plainTest

المؤلفون: Carbonara, Umberto, Amparore, Daniele, Borregales, Leonardo D, Caliò, Anna, Ciccarese, Chiara, Diana, Pietro, Erdem, Selcuk, Marandino, Laura, Marchioni, Michele, Muselaers, Constantijn H J, Palumbo, Carlotta, Pavan, Nicola, Pecoraro, Angela, Roussel, Eduard, Warren, Hannah, Wu, Zhen-Jie, Campi, Riccardo, Bertolo, Riccardo

المساهمون: Carbonara, Umberto, Amparore, Daniele, Borregales, Leonardo D, Caliò, Anna, Ciccarese, Chiara, Diana, Pietro, Erdem, Selcuk, Marandino, Laura, Marchioni, Michele, Muselaers, Constantijn H J, Palumbo, Carlotta, Pavan, Nicola, Pecoraro, Angela, Roussel, Eduard, Warren, Hannah, Wu, Zhen-Jie, Campi, Riccardo, Bertolo, Riccardo

مصطلحات موضوعية: RAPN, SP, nephrectomy, nephrooureterectomy, partial nephrectomy, pyeloplasty, renal surgery, robotic, single-port

الوصف: Single-port (SP) robotic surgery is a novel technology and is at the beginning of its adoption curve in urology. The goal of this narrative review is to provide an overview of SP-robotic partial nephrectomy (PN) 4 years after the introduction of the da Vinci SP dedicated platform, focusing on perioperative outcomes, length of stay, and surgical technique. A nonsystematic review of the literature was conducted. The research included the most updated articles that referred to SP robotic PN. Since its commercial release in 2018, several institutions have reproduced robotic PN by using the SP platform, both via a transperitoneal and a retroperitoneal approach. The published SP-robotic PN series are generally based on preliminary experiences by surgeons who had previous experience with conventional multi-arms robotic platforms. The reported outcomes are encouraging. Overall, three studies reported that SP-robotic PN cases had nonsignificantly different operative time, estimated blood loss, overall complications rate, and length of stay compared to the conventional 'multi-arms' robotic PN. However, in all these series, renal masses treated by SP had overall lower complexity. Moreover, two studies underlined decreased postoperative pain as a major pro of adopting the SP system. This should reduce/avoid the need for opioids after surgery. No study compared SP-robotic versus multi-arms robotic PN in cost-effectiveness. Published experience with SP-robotic PN has reported the feasibility and safety of the approach. Preliminary results are encouraging and at least noninferior with respect to those from the multi-arms series. Prospective comparative studies with long-term oncologic and functional results are awaited to draw more definitive conclusions and better establish the more appropriate indications of SP robotics in the field of PN.

وصف الملف: ELETTRONICO

العلاقة: info:eu-repo/semantics/altIdentifier/pmid/37325290; info:eu-repo/semantics/altIdentifier/wos/WOS:001003791600001; volume:15; numberofpages:13; journal:THERAPEUTIC ADVANCES IN UROLOGY; https://hdl.handle.net/11564/822942Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85161328882

الإتاحة: https://doi.org/10.1177/17562872231172834Test
https://hdl.handle.net/11564/822942Test

المؤلفون: Warren, Hannah, Palumbo, Carlotta, Caliò, Anna, Tran, Maxine GB, Campi, Riccardo, Courcier, Jean, Wu, Zhenjie, Bertolo, Riccardo, Pecoraro, Angela, Amparore, Daniele, Borregales, Leonardo D, Ciccarese, Chiara, Diana, Pietro, Erdem, Selçuk, Marandino, Laura, Muselaers, Stijn, Pavan, Nicola, Carbonara, Umberto, Roussel, Eduard, Marchioni, Michele

المصدر: World Journal of Urology , 41 pp. 1709-1710. (2023)

وصف الملف: text

العلاقة: https://discovery.ucl.ac.uk/id/eprint/10169819/3/Warren_Submission.pdfTest; https://discovery.ucl.ac.uk/id/eprint/10169819Test/

الإتاحة: https://discovery.ucl.ac.uk/id/eprint/10169819/3/Warren_Submission.pdfTest
https://discovery.ucl.ac.uk/id/eprint/10169819Test/

المؤلفون: Courcier, Jean, De La Taille, Alexandre, Bertolo, Riccardo, Amparore, Daniele, Erdem, Selcuk, Kara, Onder, Marchioni, Michele, Pavan, Nicola, Roussel, Eduard, Mamodaly, Maria, Campi, Riccardo, Ingels, Alexandre

المصدر: Frontiers in Oncology ; volume 13 ; ISSN 2234-943X

مصطلحات موضوعية: Cancer Research, Oncology

الوصف: Renal medullary carcinoma (RMC) is a rare form of renal cell carcinoma that has a poor prognosis. It is known to be associated with sickle cell trait or disease, although the exact underlying mechanisms are still unclear. The diagnosis is made through immunochemical staining for SMARCB1 (INI1). In this report, we present a case of a 31-year-old male patient with sickle cell trait who was diagnosed with stage III right RMC. Despite the poor prognosis, the patient survived for a remarkable duration of 37 months. Radiological assessment and follow-up were primarily performed using 18F-FDG PET/MRI. The patient underwent upfront cisplatin-based cytotoxic chemotherapy before surgical removal of the right kidney and retroperitoneal lymph node dissection. Identical adjuvant chemotherapy was administered post-surgery. Disease relapses were detected in the retroperitoneal lymph nodes; these were managed with chemotherapy and surgical rechallenges. We also discuss the oncological and surgical management of RMC, which currently relies on perioperative cytotoxic chemotherapy strategies, as there are no known alternative therapies that have been shown to be superior to date.

الإتاحة: https://doi.org/10.3389/fonc.2023.1073728Test

المؤلفون: Shrivastava, Nikita, Sharma, Gopal, Ahluwalia, Puneet, Gautam, Gagan, Erdem, Selcuk, Amparore, Daniele, Marchioni, Michele, Pavan, Nicola, Marandino, Laura, Roussel, Eduard, Campi, Riccardo, Bertolo, Riccardo

المصدر: European Urology Open Science ; volume 58, page 10-18 ; ISSN 2666-1683

مصطلحات موضوعية: Urology

الإتاحة: https://doi.org/10.1016/j.euros.2023.10.001Test
https://api.elsevier.com/content/article/PII:S2666168323012922?httpAccept=text/xmlTest
https://api.elsevier.com/content/article/PII:S2666168323012922?httpAccept=text/plainTest

المؤلفون: Bertolo, Riccardo, Pecoraro, Alessio, Carbonara, Umberto, Amparore, Daniele, Diana, Pietro, Muselaers, Stijn, Marchioni, Michele, Mir, Maria Carmen, Antonelli, Alessandro, Badani, Ketan, Breda, Alberto, Challacombe, Ben, Kaouk, Jihad, Mottrie, Alexandre, Porpiglia, Francesco, Porter, Jim, Minervini, Andrea, Campi, Riccardo, Borregales, Leonardo D., Caliò, Anna, Ciccarese, Chiara, Erdem, Selçuk, Ingels, Alexandre, Kara, Önder, Marandino, Laura, Palumbo, Carlotta, Pavan, Nicola, Pecoraro, Angela, Roussel, Eduard, Vittori, Matteo, Warren, Hannah, Wu, Zhenjie

المصدر: European Urology Open Science ; volume 52, page 7-21 ; ISSN 2666-1683

مصطلحات موضوعية: Urology

الإتاحة: https://doi.org/10.1016/j.euros.2023.03.008Test
https://api.elsevier.com/content/article/PII:S2666168323001830?httpAccept=text/xmlTest
https://api.elsevier.com/content/article/PII:S2666168323001830?httpAccept=text/plainTest

المؤلفون: Erdem, Selcuk, Bertolo, Riccardo, Campi, Riccardo, Capitanio, Umberto, Amparore, Daniele, Anceschi, Umberto, Mir, Maria Carme, Roussel, Eduard, Pavan, Nicola, Carbonara, Umberto, Kara, Onder, Klatte, Tobias, Marchioni, Michele, Pecoraro, Angela, Muselaers, Stijn, Marandino, Laura, Diana, Pietro, Borregales, Leonardo, Palumbo, Carlotta, Warren, Hannah, Wu, Zhenjie, Calio, Anna, Ciccarese, Chiara, Degirmenci, Enes, Aydin, Resat, Rebez, Giacomo, Schips, Luigi, Simone, Giuseppe, Minervini, Andrea, Serni, Sergio, Ozcan, Faruk

المساهمون: Erdem, Selcuk, Bertolo, Riccardo, Campi, Riccardo, Capitanio, Umberto, Amparore, Daniele, Anceschi, Umberto, Mir, Maria Carme, Roussel, Eduard, Pavan, Nicola, Carbonara, Umberto, Kara, Onder, Klatte, Tobia, Marchioni, Michele, Pecoraro, Angela, Muselaers, Stijn, Marandino, Laura, Diana, Pietro, Borregales, Leonardo, Palumbo, Carlotta, Warren, Hannah, Wu, Zhenjie, Calio, Anna, Ciccarese, Chiara, Degirmenci, Ene, Aydin, Resat, Rebez, Giacomo, Schips, Luigi, Simone, Giuseppe, Minervini, Andrea, Serni, Sergio, Ozcan, Faruk

مصطلحات موضوعية: Histomorphological subtype, Nonmetastatic, Papillary renal cell carcinoma, Prognosis

الوصف: Background and aim: The role of histomorphological subtyping is an issue of debate in papillary renal cell carcinoma (papRCC). This multi-institutional study investigated the prognostic role of histomorphological subtyping in patients undergoing curative surgery for nonmetastatic papRCC. Patients and methods: A total of 1,086 patients undergoing curative surgery were included from a retrospectively collected multi-institutional nonmetastatic papRCC database. The patients were divided into 2 groups based on histomorphological subtyping (type 1, n = 669 and type 2, n = 417). Furthermore, a propensity score-matching (PSM) cohort in 1:1 ratio (n = 317 for each subtype) was created to reduce the effect of potential confounding variables. The primary outcome of the study, the predictive role of histomorphological subtyping on the prognosis (recurrence free survival [RFS], cancer specific survival [CSS] and overall survival [OS]) in nonmetastatic papRCC after curative surgery, was investigated in both overall and PSM cohorts. Results: In overall cohort, type 2 group were older (66 vs. 63 years, P = 0.015) and more frequently underwent radical nephrectomy (37.4% vs. 25.6%, P < 0.001) and lymphadenectomy (22.3% vs. 15.1%, P = 0.003). Tumor size (4.5 vs. 3.8 cm, P < 0.001) was greater, and nuclear grade (P < 0.001), pT stage (P < 0.001), pN stage (P < 0.001), VENUSS score (P < 0.001) and VENUSS high risk (P < 0.001) were significantly higher in type 2 group. 5-year RFS (89.6% vs. 74.2%, P < 0.001), CSS (93.9% vs. 84.2%, P < 0.001) and OS (88.5% vs. 78.5%, P < 0.001) were significantly lower in type 2 group. On multivariable analyses, type 2 was a significant predictor for RFS (HR:1.86 [95%CI:1.33-2.61], P < 0.001) and CSS (HR:1.91 [95%CI:1.20-3.04], P = 0.006), but not for OS (HR:1.27 [95%CI:0.92-1.76], P = 0.150). In PSM cohort balanced with age, gender, symptoms at diagnosis, pT and pN stages, tumor grade, surgical margin status, sarcomatoid features, rhabdoid features, and presence of ...

العلاقة: info:eu-repo/semantics/altIdentifier/pmid/38443238; volume:42; issue:5; firstpage:1; lastpage:13; numberofpages:13; journal:UROLOGIC ONCOLOGY; https://hdl.handle.net/11562/1121167Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85186664588

الإتاحة: https://doi.org/10.1016/j.urolonc.2024.01.028Test
https://hdl.handle.net/11562/1121167Test